Infographic: efficacy and safety of teprotumumab in patients with thyroid eye disease of long duration and low disease activity

Eye 2026 Open access

Read full text
Authors: Erind Alushaj, Gabriele Berman, Michael Lowe, Susan P. Mollan, Sarah M. Simpson
DOI: 10.1038/s41433-026-04696-7
Cited by: 1
References: 3

Abstract

Fig. 1 Full size image Teprotumumab is a monoclonal antibody therapy targeting insulin-like growth factor-1 receptor for active thyroid eye disease (TED) [ 1 , 2 ]. This infographic summarises the design and results of the phase VI multicentre trial which evaluated the efficacy, safety, and tolerability of teprotumumab in patients with longstanding TED (2-10 years disease duration) and low clinical disease activity (CAS ≤ 1) [ 2 ]. Teprotumumab reduced proptosis in patients with chronic TED [ 2 , 3 ].

Fields of Study & Subjects

Ophthalmology and Eye Disorders Ocular Diseases and Behçet’s Syndrome Connexins and lens biology

Publication details

Journal / source
Eye
Publisher
Springer Science and Business Media LLC
Publication date
3 July 2026
Language
EN